AstraZeneca posts transcript of Sustainability Investor Call on sustainability highlights

• AstraZeneca’s July 2026 sustainability investor call featured Executive Vice President, Global Operations, IT and Chief Sustainability Officer Pam Cheng, joined by the Vice President, Policy, Advocacy and Health Equity, the Vice President, Global Sustainability and Safety, Health & Environment, and the Director, Investor Relations.
• Management highlighted an 88% cut in Scope 1 and 2 emissions versus 2015, with more than 80% of supplier spend tied to science-based targets.
• Scope 3 plan centers on shifting pressurized metered dose inhalers to a near-zero global-warming propellant; management put pMDIs at about 25% of Scope 3 footprint.
• Transition progress cited completion in the UK, France, Spain, Portugal, Germany; regulatory submissions underway in the US, China, Japan.
• Health equity goals include 1 billion people positively impacted by 2030, including 400 million from underserved groups; 156 million impacted since 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.